Guidance for Industry (GFI): Expedited Programs for Serious Conditions-Drugs and Biologics
Revision of a currently approved collection
No
Regular
Approved without change
04/27/2018
02/13/2018
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
04/30/2021
36 Months From Approved
05/31/2020
514
0
193
34,730
0
10,310
0
0
0
This ICR collects information from sponsors and applicants who wish to obtain a priority review designation or breakthrough therapy designation. Respondents to the collection are manufacturers or sponsors of drug and/or biologic products.
US Code:
21 USC 356
Name of Law: FFDCA; Fast track products
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.